m6A在R回路恒温的修改:癌症治疗药物的潜在目标
Minh-Anh Vu1, Manuela Spagnuolo1, Chun-Long Chen1
1Institut Curie, PSL Research University, CNRS UMR3244, Dynamics of Genetic Information, Sorbonne Université, 75005 Paris, France.
NAR cancer
|August 14, 2025
概括
N6-甲基氨酸 (m6A) 调节DNA-RNA混合 (R-loop) 稳定性,影响基因表达和基因组完整性. 了解这个m6A-R循环轴提供了治疗潜力.
科学领域:
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 基因组学就是基因组学.
背景情况:
- R环 (DNA-RNA杂交) 对于基因调节至关重要,但如果未解决,可能会导致基因组不稳定.
- 最丰富的mRNA修饰N6-Methyladenosine (m6A) 越来越多地被认为是它在R循环稳态中的作用.
- m6A对R循环形成和分辨率的确切影响取决于背景,呈现出一个复杂的监管网络.
研究的目的:
- 审查m6A在调节R循环动态中的多方面的作用.
- 探索m6A如何影响与R循环相关的过程,如转录,DNA修复和中间体/端粒稳定性.
- 讨论m6A,新生的转录,染色质和R循环动态之间的相互作用.
主要方法:
- 对调查m6A和R-循环相互作用的研究的文献综述.
- 对m6A对基因表达,DNA修复和基因组稳定性影响的研究分析.
- 与R循环形成和分辨率的m6A介导调节相关的发现的综合.
主要成果:
- 根据特定的细胞环境,m6A修饰可以稳定或促进R循环的分辨率.
- m6A影响了关键基因组过程中的R循环动态,包括转录和DNA修复.
- 新出现的证据将m6A与染色质修饰和新生的转录联系起来,进一步调节R循环行为.
结论:
- m6A-R循环轴是基因组稳定性的关键决定因素.
- 需要进一步的研究,以充分阐明控制m6A在R回路调节中的双重作用的机制.
- 针对m6A-R循环途径为新型治疗策略提供了一个有希望的途径.
更多相关视频
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
266
08:29SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
7.2K
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:38Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K